Injection Anxiety and Dose Titration Failures as Structural Drivers of Early GLP-1 Abandonment
Needle anxiety and titration nausea drive early GLP-1 dropout.
Marcus Oyelaran
Section
GLP-1 Therapeutics
7 stories in GLP-1 Therapeutics.
Weight Loss Versus Metabolic Benefit in GLP-1 Therapy
The drugs' real power lies in tissue-specific effects that exist independent of weight loss.
Daniel Ngô
GLP-1 Receptor Agonists in Type 1 Diabetes and Non-Obesity Indications
Trial data shows GLP-1 drugs reduce heart risk in type 1 diabetes.
Cecilia Brandt-Kowalski
GLP-1 Receptor Distribution in the Brain and CNS Pharmacology
Brain GLP-1 receptors span reward, appetite, and cognition circuitry, reshaping how the drugs work.
Cecilia Brandt-Kowalski
Peptide Stability Challenges in GLP-1 Analog Formulation
Every stabilizing trick introduces new failure modes that complicate drug development elsewhere.
Cecilia Brandt-Kowalski
Nausea Mechanisms in GLP-1 Therapy and Formulation Solutions
Targeting the brainstem can reduce nausea without sacrificing GLP-1's metabolic benefits.
Priya Subramaniam
GLP-1 Injectable Dropout Rates and the Compliance Crisis
Most patients stop GLP-1 injections within a year, often before reaching effective doses.
Cecilia Brandt-Kowalski